Skip to content
DataLookout
Menu

NCT06013423

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 13 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 6 words Show 4 more changesShow less
    • Interventions modified
    • Secondary endpoints: details revised at 3 of 12 entries
    • Study description expanded, about 7 words
    • Site details revised
  2. Minor Study description expanded, about 7 wordsv12
  3. Minor Start date changed from estimate of Sep 1, 2024 to Jul 23, 2024v11
  4. Notable Primary completion date: Oct 31, 2024 to Oct 31, 2031
    • Study completion date: Oct 31, 2025 to Oct 31, 2032
    • Start date: Aug 8, 2024 to Sep 1, 2024
    v10
  5. Notable Start date: Jul 6, 2024 to Aug 8, 2024v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Start date: Jun 3, 2024 to Jul 6, 2024v8
  2. Notable Start date: May 3, 2024 to Jun 3, 2024v7
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 15, 2024 to May 3, 2024
    • Site details revised
    v6
  4. Notable Start date: Mar 15, 2024 to May 15, 2024v5
  5. Minor Start date: Feb 15, 2024 to Mar 15, 2024v4
  6. Notable Eligibility criteria shortened, about 7 words
    • Start date: Feb 6, 2024 to Feb 15, 2024
    v3
  7. Notable Start date: Jan 1, 2024 to Feb 6, 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall survival
Timeframe: At 1 year

Secondary (12)

Cumulative incidence of neutrophil and platelet engraftment
Incidences of graft failure
Incidence of grade II-IV and III-IV acute graft-versus-host disease (aGVHD)
Incidence of grade II-IV and III-IV aGVHD
Incidence of chronic graft-versus-host disease (cGVHD)
Show 7 moreShow less
Organ distribution of GVHD
Incidence of adverse events
Time to immunosuppression cessation
Pattern of donor chimerism
Incidence of pre-engraftment syndrome (PES)
Incidence of transplant related mortality (TRM)
Incidence of relapse

Arms and interventions

Arm I (myeloablative UCBT)Experimental

See detailed description.

Arm II (myeloablative UCBT)Experimental

See detailed description.

Procedures: Biospecimen Collection, Bone Marrow Aspirate, Diagnostic Imaging Testing, Echocardiography Test, Multigated Acquisition Scan, Umbilical Cord Blood Transplantation

Drugs: Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Thiotepa

Other: Survey Administration

Radiation: Total-Body Irradiation

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States